Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial
VAPOR-C is a randomised study of the impact of IV versus inhaled anaesthesia (propofol versus sevoflurane) and lidocaine versus no lidocaine on duration of disease free survival inpatients with either colorectal or non small cell lung cancer.
Checked against the public recordLast updated Mar 14, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Other
- Study type
- Interventional
- Phase
- Phase 3
- Sponsor
- Peter MacCallum Cancer Centre, Australia
- Interventions being studied
- Drug: Sevoflurane; Drug: Propofol; Drug: Lidocaine IV
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: 1. Male or female patients aged 18 years or older at screening 2. Has provided written informed consent for the trial 3. Patient with American Joint committee on Cancer (AJCC) 8th edition Stage I-III colorectal cancer or Stage I-IIIa NSCLC, as confirmed by histological or cytological diagnosis. In cases where a histological diagnosis is not possible, suspected diagnosis through imaging techniques is acceptable. 4. Patient has an American Society of Anaesthesiologists (ASA) score of 1 to 3 5. Scheduled to receive elective, surgical resection with curative intent 6. Surgery expected to last ≥2 hours and expected to require ≥2 nights hospital stay 7. Able to comply with protocol requirements and follow-up procedures Exclusion Criteria: 1. Confirmed or suspected allergy to propofol, sevoflurane or intravenous lidocaine 2. Patient with significant liver disease (with elevated International Normalised Ratio (INR) or bilirubin and/or low albumin; i.e. Childs-Pugh Score \>Class A; 3. Patient at personal or familial risk of malignant hyperthermia or porphyria 4. Patient with a history of other malignancies within the past 5 years. However, patients with malignancies managed with curative therapy and considered to be at low risk of recurrence such as treated skin basal cell carcinoma, squamous cell carcinoma, malignant melanoma ≤1.0mm without ulceration, localised thyroid cancer, cervical carcinoma in situ or prior malignancies with high likelihood of cure (e.g. low grade prostate and breast cancer) may be included in the study 5. Patient has distant metastases 6. Patient with an actual body weight less than 45kg 7. Patients taking the following drugs that are moderate-strong inhibitors of the CYP1A2 and CYP3A4 metabolic pathways within 72 hours prior to surgery: Antibiotics - 'mycin' class: Clarithromycin, Telithromycin, Azithromycin, Erythromycin Antibiotics - 'floxacin' class Ciprofloxacin (exception: can be used preoperatively within a bowel prep regime), Norfloxacin, Levofloxacin, Sparfloxacin Antibiotics - other: Chloramphenicol, Isoniazid Antifungals: Fluconazole, Itraconazole, Ketoconazole, Posaconazole, Voriconazole Antiretrovirals: Atazanavir; Darunavir; Indinavir; Lopinavir; Nelfinavir; Ombitasvir, Paritaprevir, Ritonavir and Saquinavir. Antidepressants/ADHD: Fluvoxamine, Enoxacine. Calcium-channel blockers: Diltiazem, Verapamil Monoclonal Antibodies: Ceritinib, Idelalisib, Lonafarnib, Tucatinib. Other strong cytochrome P450 3A4 inhibitors: Cimetidine, Cobicistat; grapefruit juice, Mifepristone, Nefazodone.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Cleveland ClinicCleveland, Ohio
- University of Pittsburgh Medical CenterPittsburgh, Pennsylvania
- The University of Texas MD Anderson Cancer CentreHouston, Texas
- Chris O'Brien LifehouseCamperdown, New South Wales
- Royal Prince Alfred HospitalCamperdown, New South Wales
- Prince of Wales HospitalRandwick, New South Wales
- Royal Brisbane and Women's HospitalHerston, Queensland
- Mackay Base HospitalMackay, Queensland
- RedCliffe HospitalRedcliffe, Queensland
- Rockhampton HospitalRockhampton, Queensland
- Gold Coast University HospitalSouthport, Queensland
- Princess Alexandra HospitalWoolloongabba, Queensland
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 14, 2025. Always confirm current availability with the study team.